Great Elm Capital Corp. - 8.75% Notes due 2028 Stock (NASDAQ: GECCZ)

Latest news for Great Elm Capital Corp. - 8.75% Notes due 2028 (NASDAQ:GECCZ) Stock

Great Elm Capital Corp. - 8.75% Notes due 2028

News

Merck Announced That The National Medical Products Administration Of China Approved Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, And 18) Vaccine] For Use In Males 9-26 Years Of Age To Help Prevent Certain HPV-related Cancers And Diseases

Guidance

HELE

Helen Of Troy Sees Lowers FY25 Revenue Outlook To $1.888B - $1.913B Vs. $1.91B Est.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</h3>
<ul>
<li>Dividend Yield: 7.10%</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and cut the price target from $60 to $55 on Dec. 10, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Mizuho analyst John Roberts maintained a Neutral rating and cut the price target from $50 to $46 on Dec. 9, 2024. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Dec. 18, Dow and Innventure agreed to collaborate on waste-to-value platform.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1">latest DOW news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064729/image-41.png" alt="" class="wp-image-723747" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064729/image-41.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064729/image-41-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064729/image-41-768x704.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul>
<li>Dividend Yield: 5.90%</li>
<li>Mizuho analyst Kieran De Brun maintained a Neutral rating and cut the price target from $23 to $21 on Jan. 7. This analyst has an accuracy rate of 66%.</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and lowered the price target from $26 to $25 on Nov. 6, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Nov. 4, Huntsman reported worse-than-expected third-quarter sales results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1"> latest HUN news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064802/image-42.png" alt="" class="wp-image-723748" style="width:495px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064802/image-42.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064802/image-42-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064802/image-42-768x702.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>)</h3>
<ul>
<li>Dividend Yield: 5.33%</li>
<li>Mizuho analyst John Roberts maintained a Neutral rating and decreased the price target from $22 to $21 on Jan. 7. This analyst has an accuracy rate of 74%.</li>
<li>Morgan Stanley analyst Vincent Andrews maintained an Equal-Weight rating and cut the price target from $30 to $25 on Nov. 5, 2024. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On Jan. 7, Chemours named Google executive Joseph Kava to its Board of Directors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1">latest CC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010825&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064837/image-43.png" alt="" class="wp-image-723751" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064837/image-43.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064837/image-43-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08064837/image-43-768x702.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields

Stifel analyst W. Andrew Carter reinstates Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and announces $175 price target.

Initiation

BLDR

Stifel Reinstates Buy on Builders FirstSource, Announces $175 Price Target

W&T Offshore Disclosed That It Recently Signed A Purchase And Sale Agreement To Sell A Non-core Interest In Garden Banks Blocks 385 And 386 Which Included Latest Net Production Of About 195 Barrels Of Oil Equivalent Per Day (boe/d) (72% Oil) For $12.3M

Stifel analyst W. Andrew Carter reinstates Beacon Roofing Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>) with a Buy and announces $115 price target.

BECN

Stifel Reinstates Buy on Beacon Roofing Supply, Announces $115 Price Target

Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.60 by 2.69 percent. This is a 4.3 percent decrease over earnings of $2.79 per share from the same period last year. The company reported quarterly sales of $549.61 million which beat the analyst consensus estimate of $534.31 million by 2.86 percent. This is a 0 percent decrease over sales of $549.61 million the same period last year.

Earnings

Earnings Beats

Helen Of Troy Q3 Adj $2.67 Beats $2.60 Estimate, Sales $549.61M Beat $534.31M Estimate

Needham analyst Scott Berg maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and raises the price target from $375 to $400.

Needham Maintains Buy on Salesforce, Raises Price Target to $400

Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $1126 to $1004.

REGN

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1004

Needham analyst Bernie McTernan maintains Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy and maintains $300 price target.

FLUT

Needham Maintains Buy on Flutter Entertainment, Maintains $300 Price Target

<a href="https://www.cnn.com/2025/01/08/economy/trump-national-economic-emergency-tariffs/index.html" title="https://www.cnn.com/2025/01/08/economy/trump-national-economic-emergency-tariffs/index.html">https://www.cnn.com/2025/01/08/economy/trump-national-economic-emergency-tariffs/index.html</a>

Macro Economic Events

Politics

Economics

General

CNN Reported President Elect Trump Is Considering A National Economic Emergency Declaration To Allow For New Tariff Program

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $302 to $220.

BIIB

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $220

Truist Securities analyst Robyn Karnauskas maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Hold and lowers the price target from $333 to $298.

AMGN

Truist Securities Maintains Hold on Amgen, Lowers Price Target to $298

HC Wainwright &amp; Co. analyst Ed Arce maintains Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $4 price target.

UNCY

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Maintains $4 Price Target

Truist Securities analyst Robyn Karnauskas maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Buy and raises the price target from $62 to $65.

Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $11 price target.

PSNL

HC Wainwright & Co. Maintains Buy on Personalis, Maintains $11 Price Target

Truist Securities analyst Srikripa Devarakonda maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and lowers the price target from $215 to $211.

ABBV

Truist Securities Maintains Buy on AbbVie, Lowers Price Target to $211

Health Care

ANGO

AngioDynamics Expects 2025 Adjusted EPS Loss Of $0.34 to $0.38 Compared To Prior Guidance Of $0.38-$0.42 And Consensus Of $0.40

Truist Securities analyst Robyn Karnauskas downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Hold and lowers the price target from $130 to $110.

Downgrades

Truist Securities Downgrades Merck & Co to Hold, Lowers Price Target to $110

Needham analyst Mike Matson maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and maintains $7.25 price target.

Needham Maintains Buy on Personalis, Maintains $7.25 Price Target

Great Elm Capital Corporation (GECC) Q4 2023 Earnings Call Transcript

New Preferred Stock And Exchange Traded Debt IPOs, April 2024

Great Elm Capital Corporation 2024 Q1 - Results - Earnings Call Presentation

Great Elm Capital Corporation (GECC) Q1 2024 Earnings Call Transcript

Great Elm Capital Corporation 2024 Q2 - Results - Earnings Call Presentation

Great Elm Capital Corp. (GECC) Q2 2024 Earnings Call Transcript

Pivotal Moment For BDC Dividend Investors, Here Is What To Do

Great Elm Capital Corporation 2024 Q3 - Results - Earnings Call Presentation

Great Elm Capital Corporation (GECC) Q3 2024 Earnings Call Transcript

ARCC

BBDC

BIZD

CCAP

FDUS

GAIN

GAINL

GAINN

GAINZ

GECC

GECCH

GECCI

GECCM

GECCO

GECCZ

GLAD

GLADZ

LRFC

MAIN

MFAN

MFAO

MGRB

MGRD

MGRE

OCSL

PBDC

PFLT

PNNT

TCPC

TPVG

WHFCL

Press Releases

Great Elm Capital Corp. Announces Fourth Quarter and Full Year 2023 Financial Results

Great Elm Capital Corp. Announces First Quarter 2024 Financial Results

Great Elm Capital Corp. Announces Second Quarter 2024 Financial Results

Great Elm Capital Corp. Announces Third Quarter 2024 Financial Results

Comments

Great Elm Capital Corp. - 8.75% Notes due 2028

News

Latest news for Great Elm Capital Corp. - 8.75% Notes due 2028 (NASDAQ:GECCZ) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga